^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD8-H

    i
    Other names: CD8, CD8A, cluster of differentiation 8, CD8a Molecule, T-Cell Surface Glycoprotein CD8 Alpha Chain, T-Lymphocyte Differentiation Antigen T8/Leu-2, CD8 Antigen, Alpha Polypeptide (P32), Leu2 T-Lymphocyte Antigen, OKT8 T-Cell Antigen, T-Cell Antigen Leu2, T Cell Co-Receptor, T8 T-Cell Antigen, CD8a Antigen
    Entrez ID:
    925
    Related biomarkers:
    Expression
    Others
    21h
    Spatial distributions of CD8 and Ki67 cells in the tumor microenvironment independently predict breast cancer-specific survival in patients with ER+HER2- and triple-negative breast carcinoma. (PubMed, PLoS One)
    Computational biomarkers, representing spatial properties of the tumor proliferation and immune cell infiltrates, provided independent prognostic information beyond conventional IHC markers in BC. Integrating Ki67-entropy and CD8-immunogradient indicators into prognostic models can improve patient stratification with regard to BCSS.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8)
    |
    HER-2 positive • ER positive • HER-2 negative • CD8 positive • CD8-H • HER-2 negative + ER positive
    3d
    Prognostic significance of CD8 and TCF1 double positive T cell subset in microsatellite unstable gastric cancer. (PubMed, Sci Rep)
    Multivariable Cox-regression identified CD8+/TCF1 + to CD8 + ratio as an independent prognostic factor (p = 0.028). We demonstrated the prognostic significance of CD8+/TCF1 + to CD8 + ratio using double IHC in a large cohort of MSI-H GC.
    Journal
    |
    MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • ITGAE (Integrin Subunit Alpha E)
    |
    MSI-H/dMMR • CD8-H
    3d
    Efficacy of Xihuang capsules as an adjuvant treatment for metastatic colorectal cancer and its impact on immune function (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
    They not only enhance patients' quality of life and reduce the toxic and adverse effects of chemotherapy, but also improve immune function. These benefits are particularly significant in patients with a high tumor burden, indicating that Xihuang capsules are worthy of clinical application.
    Retrospective data • Journal • Metastases
    |
    CD8 (cluster of differentiation 8) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • HMGB1 (High Mobility Group Box 1)
    |
    CD8-H
    8d
    LAG-3 Expression, γδ-T cell/MHC-I Interactions and Prognosis in Merkel Cell Carcinoma. (PubMed, Lab Invest)
    Overall, LAG-3 is expressed in MCC infiltrates and is prognostic in pre-immunotherapy MCC, suggesting a potential role for LAG-3 inhibition in MCC. Additionally, CD8 and γδ-T cells may play a critical role in the response to MCC, and γδ-T cell density may represent a novel biomarker in MCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
    |
    PD-L1 expression • CD8 expression • LAG3 expression • CD8-H
    17d
    Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcoma. (PubMed, Ther Adv Med Oncol)
    Immunomodulatory interventions may hold promise, as evidenced by PD-L1 expression and CD8+ infiltration. Further research, including larger cohorts and international collaborations, is needed to validate these findings and explore therapeutic strategies targeting L1CAM in ASPS.
    Journal • PD(L)-1 Biomarker • IO biomarker • Immunomodulating
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FASLG (Fas ligand) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • ASPSCR1 (ASPSCR1 Tether For SLC2A4) • L1CAM (L1 cell adhesion molecule)
    |
    PD-L1 expression • CD8-H • TFE3 fusion
    1m
    The combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers. (PubMed, J Pathol Transl Med)
    Altogether, a high density of CD8 iTILs did not make a difference in the survival of patients with CRC with CDX2 loss. The combination of CDX2 expression and intraepithelial CD8 TIL density was an independent prognostic marker in adjuvant chemotherapy-treated patients with stage III CRC.
    Journal • Tumor-infiltrating lymphocyte
    |
    CD8 (cluster of differentiation 8) • CDX2 (Caudal Type Homeobox 2)
    |
    CD8-H • CDX-2 expression
    |
    5-fluorouracil • leucovorin calcium
    2ms
    Integrative analysis of H&E and IHC identifies prognostic immune subtypes in HPV related oropharyngeal cancer. (PubMed, Commun Med (Lond))
    Integrating H&E and IHC data enhances the functional characterization of immune phenotypes of the TME with biological interpretability, and improves patient stratification in HPV( + ) OPSCC.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule)
    |
    CD8 expression • CD8-H • CD163 expression • CD163 underexpression
    2ms
    Special tissue microbiota such as Cyanobacteria are associated with the immune microenvironment of lung adenocarcinoma. (PubMed, Transl Cancer Res)
    Our study indicated that the lung microbiota played an indispensable role in the CD8+ T cell-mediated tumor immune response. These findings shed light on valuable insights into the intricate interplay between the lung microbiome and the immune system in the progression of lung cancer, offing potential therapeutic strategies targeting the lung microbiome.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    PD-1 expression • CD8 expression • CD8-H
    2ms
    A comprehensive landscape analysis of autophagy in cancer development and drug resistance. (PubMed, Front Immunol)
    In vitro, dihydroartemisinin and artesunate could reverse breast cancer doxorubicin resistance, through inducing autophagy via upregulating LC3B and ATG7. Our study provided a comprehensive landscape of the autophagy-related molecular and tumor microenvironment patterns for cancer progression and resistance, and highlighted the promising potential of drug-induced autophagy in the activation of drug sensitivity and reversal of resistance.
    Journal
    |
    CD8 (cluster of differentiation 8) • ATG7 (Autophagy Related 7)
    |
    CD8-H
    |
    doxorubicin hydrochloride
    4ms
    IMMUNOREACT 11: IMMUNE PREDICTORS OF RELAPSE AFTER ADJUVANT THERAPY IN RECTAL CANCER PATIENTS (UEGW 2024)
    Our preliminary data suggest that the immune-related markers signature in the healthy peritumoral mucosa might be useful for predicting relapse after adjuvant therapy in rectal cancer patients. Moreover, relapsing patients showed lower stimulation of macrophages and lymphocytes, thus suggesting that impaired immune surveillance might influence adjuvant therapy outcomes. Sampling healthy mucosa might help the decision-making about adjuvant therapy after surgery for rectal cancer.
    Clinical • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • IL2RA (Interleukin 2 receptor, alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD28 (CD28 Molecule) • CCL8 (C-C Motif Chemokine Ligand 8) • FOXP3 (Forkhead Box P3) • TNFSF13B (TNF Superfamily Member 13b) • IL1R1 (Interleukin 1 receptor, type I) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20) • SIGLEC1 (Sialic Acid Binding Ig Like Lectin 1) • MS4A6A (Membrane Spanning 4-Domains A6A)
    |
    CD38 expression • IL2RA expression • CD8-H
    |
    nCounter® PanCancer IO 360™ Panel
    6ms
    High immune cell infiltration predicts improved survival in cholangiocarcinoma. (PubMed, Front Oncol)
    Identifying patient subgroups that could benefit from immunotherapy with PD-1/PD-L1 pathway blockade may help improve treatment strategies for this aggressive cancer. Our findings highlight the importance of evaluating the immune contexture in cholangiocarcinoma, as ICS serves as a strong independent prognostic and selective factor for patients who might benefit from immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker • Immune cell
    |
    CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • PD-1 expression • CD8-H
    6ms
    Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction. (PubMed, Oncoimmunology)
    Furthermore, CD39 expression was associated with unfavorable clinical parameters. Expression of CD39 on T cells was upregulated through CD3/CD28 stimulation and its blockade by a newly developed nanobody construct resulted in increased proliferation (eFluor), activation (CD25 and CD134), and production of cytotoxic cytokines (IFN-γ, TNF-α, and granzyme-B) of CD8+ T cells.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD73 (5'-Nucleotidase Ecto) • IL2RA (Interleukin 2 receptor, alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD24 (CD24 Molecule) • GZMB (Granzyme B) • TNFRSF4 (TNF Receptor Superfamily Member 4) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    CD73 expression • CD8-H • TIGIT expression • ENTPD1 expression
    7ms
    Identification and Quantification of Radiotherapy-related Protein Expression in Cancer Tissues Using the Qupath Software and Prediction of Treatment Response. (PubMed, In Vivo)
    QuPath showed a strong correlation with manual counting, confirming its utility and accuracy and potential applicability in clinical practice.
    Journal
    |
    CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3)
    |
    CD8-H
    7ms
    Prognostic Effect of Tertiary Lymphoid Structures in Epstein-Barr Virus-associated Gastric Carcinomas measured by Digital Image Analysis. (PubMed, Lab Invest)
    Patients with a low TLS ratio (p=0.038), low HEV density (p=0.042), and ectopic tumor MECA-79 expression (p=0.032) had significantly worse prognoses. In conclusion, the TLS ratio and HEV density affect the survival of patients with EBVaGC and may be related to the immune response that interrupts lymph node metastasis.
    Journal
    |
    CD8 (cluster of differentiation 8) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    CD8-H
    7ms
    Characterization of polyamine metabolism predicts prognosis, immune profile, and therapeutic efficacy in lung adenocarcinoma patients. (PubMed, Front Cell Dev Biol)
    Finally, immunotherapy and chemotherapy may be beneficial to the high-PMRS group based on the immunotherapy cohorts and low half-maximal inhibitory concentration (IC50) values. We identified distinct polyamine modification patterns and established a PMRS to provide new insights into the mechanism of polyamine action and improve the current anti-tumor strategy of LUAD.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PSMC6 (Proteasome 26S Subunit, ATPase 6)
    |
    CD8-H
    8ms
    IL7 in combination with radiotherapy stimulates a memory T-cell response to improve outcomes in HNSCC models. (PubMed, Cancer Immunol Immunother)
    IL7 also expanded a memory-like subpopulation of CD8 T-cells. These results indicate that IL7 in combination with RT can serve as an effective immunotherapy strategy outside of the conventional ICB axis to drive the antitumor activity of CD8 T-cells.
    Journal • Combination therapy
    |
    CD8 (cluster of differentiation 8) • IL7 (Interleukin 7)
    |
    CD8-H
    8ms
    Prognostic Values of CD8+, PARP, and EGFR on Overall Survival in Patients with Triple-Negative Breast Cancer. (PubMed, Asian Pac J Cancer Prev)
    Patients with low CD8+, positive PARP, and positive EGFR expressions seem to be associated with poorer overall survival in TNBC. After approximately one year of follow-up, higher survival was observed in patients with high CD8+, negative PARP, and negative EGFR. Staging remains the main predictor of TNBC survival. Therefore, early detection and treatment of TNBC are essential to improve survival.
    Journal • PARP Biomarker
    |
    EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    EGFR expression • CD8 expression • EGFR positive • EGFR negative • CD8-H • CD8 negative
    8ms
    CD8-positive T Cell Infiltration With Human Leukocyte Antigen Class 1 Expression Predicts Patients With Stage IV Colorectal Cancer Survival. (PubMed, Anticancer Res)
    The combination of CD8+ T cell infiltration and HLA1 expression is crucial for cancer immune microenvironment evaluation in CRCs.
    Journal • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    CD8 expression • CD8 positive • CD8-H
    8ms
    CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production. (PubMed, Front Immunol)
    These findings highlight the multifaceted roles of CD81 and CD82 in T cell activation, cytokine production, memory subset accumulation, and target cell cytolysis. Therefore, these findings suggest the potential of CD81 and CD82 as promising candidates for co-stimulatory molecules in immune therapeutic strategies for cancer treatment within the intricate TME.
    Journal • Tumor-infiltrating lymphocyte
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • CD81 (CD81 Molecule)
    |
    CD8-H • IL2 expression
    8ms
    Cancer-associated fibroblast spatial heterogeneity and EMILIN1 expression in the tumor microenvironment modulate TGF-β activity and CD8+ T-cell infiltration in breast cancer. (PubMed, Theranostics)
    Our data show that correlating TGF-β signaling to a CAF subpopulation is not enough because proteins with TGF-β-modulating activity originating from other CAF subpopulations can alter its activity. Therefore, therapeutic targeting should remain focused on biological processes rather than on specific CAF subtypes.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    CD8-H
    8ms
    Tumor-infiltrating immune cells and survival in head and neck squamous cell carcinoma: a retrospective computational study. (PubMed, Sci Rep)
    Immune cell clusters with four distinct survival profiles were discovered, of which the cluster with a high CD8+ T cell content had a better prognosis. The immune-infiltration pattern is related to the survival of HNSCC to varying degrees depending on the tumor sites; forthcoming studies into immune-mediated infiltration profiles will lay the groundwork for treating HNSCC with precision therapy.
    Retrospective data • Journal • IO biomarker • Immune cell
    |
    CD8 (cluster of differentiation 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • CXCR6 (C-X-C Motif Chemokine Receptor 6)
    |
    CD8-H • TIGIT expression
    8ms
    Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors. (PubMed, J Cancer Res Clin Oncol)
    Our study highlights the predictive value of IHC-classified subtypes and CD8-positive cell infiltration in estimating outcomes for patients with ED-SCLC treated with chemoimmunotherapy as a first-line therapy. These findings have practical implications for daily clinical assessments and treatment decisions.
    Journal • Checkpoint inhibition • IO biomarker • Biopsy
    |
    CD8 (cluster of differentiation 8) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1)
    |
    CD8 positive • CD8-H
    8ms
    rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors. (PubMed, J Immunother Cancer)
    rhIL-7-hyFc can expand and maintain the progenitor pool of exhausted CD8+ T cells, whereas hIL-2/TCB2c promotes their differentiation into TEX term. Together, this induces an immune-stimulatory TME that improves the efficacy of checkpoint blockade.
    Journal • Checkpoint inhibition
    |
    CD8 (cluster of differentiation 8) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL7 (Interleukin 7)
    |
    CD8-H
    |
    Hyleukin-7 (efineptakin alfa) • SLC-3010
    8ms
    Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer. (PubMed, Cancer Sci)
    These results suggest that ICIs were effective in patients with GBC. High CEA level, cutaneous irAEs, high CD8+ T cell infiltration, and immune inflamed phenotype could be useful for predicting the efficacy of ICIs in GBC.
    Journal • Checkpoint inhibition • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    CD8-H
    9ms
    First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study. (PubMed, BMC Endocr Disord)
    The combination of lenvatinib and pembrolizumab was effective and moderately tolerated in treatment-naïve ATC patients with occasional long-lasting response. However, we could not confirm the exceptional responses for this combination therapy reported before in pretreated patients.
    Retrospective data • Journal • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    CD8-H
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    9ms
    Tumor stroma ratio, tumor stroma maturity, tumor-infiltrating immune cells in relation to prognosis, and neoadjuvant therapy response in esophagogastric junction adenocarcinoma. (PubMed, Virchows Arch)
    Notably, the combined model incorporating TSM and CD163+TAM can contribute significantly to prognostic stratification. Additionally, high stromal levels evaluated in preoperative biopsy specimens correlated with poor neoadjuvant therapy response.
    Journal • Stroma • Immune cell
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    CD8-H
    9ms
    Prognostic significance and immune escape implication of tumor-infiltrating neutrophil plasticity in human head and neck squamous cell carcinoma. (PubMed, Hum Cell)
    We identify HNSCC-infiltrating N2/N1 neutrophil plasticity as a crucial prognostic indictor which potentially reflects the tumor microenvironment (TME) and immune escape landscape within HNSCC tissues. Further investigations and validations may provide novel therapeutic strategies for personalized immunomodulation in HNSCC patients.
    Journal
    |
    CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3)
    |
    CD8-H
    9ms
    Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes. (PubMed, Cancer Immunol Immunother)
    Multivariate analysis in Luminal type A patients revealed that increased CD163 + was independently associated with a higher relapse rate (HR = 2.360; 95% CI 1.077-5.170; p = 0.032). This study demonstrates that the evaluation of the functional status of CD8 + T cells in combination with the analysis of immunosuppressive elements could provide clinically relevant information in different breast cancer subtypes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule)
    |
    PD-L1 expression • CD8-H
    10ms
    The Prognostic Value of Tumor Infiltrating Lymphocytes After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis. (PubMed, Clin Genitourin Cancer)
    TILs are useful prognostic markers in patients treated with RC for BC. Although the prognostic value of TILs is varied, depending on the subset and infiltration site, CD8+ TILs and intratumoral TILs are associated with oncologic outcomes. Further studies are warranted to explicate the predictive value of TILs on the response to perioperative systemic therapy to help clinical decision-making in patients with BC.
    Retrospective data • Review • Journal • Tumor-infiltrating lymphocyte
    |
    CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3)
    |
    CD8-H
    10ms
    Profiling Fibroblast Growth Factor Receptor 3 Expression Based on the Immune Microenvironment in Upper Tract Urothelial Carcinoma. (PubMed, Eur Urol Oncol)
    Although most patients exhibit a poor response to Pem, individuals with low FGFR3 expression and immune hot status may benefit clinically from Pem treatment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • FGFR3 (Fibroblast growth factor receptor 3) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • MSR1 (Macrophage Scavenger Receptor 1)
    |
    FGFR3 mutation • CD8-H • FGFR3 expression • CD4 expression
    |
    Keytruda (pembrolizumab)
    10ms
    Blood Lymphocytes as a Prognostic Factor for Stage III Non-Small Cell Lung Cancer with Concurrent Chemoradiation. (PubMed, Chonnam Med J)
    TLC reduction during CCRT is a significant prognostic factor for PFS, and heart V20 is significantly associated with TLC reduction. Thus, in the era of immunotherapy, constraining the volume of the radiation dose to the whole heart must be prioritized for the better survival outcomes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • CD8-H
    10ms
    Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma. (PubMed, Cancer Immunol Immunother)
    Intrapatient comparison of progressive versus regressive lesions indicates no defect in tumor T cell infiltration, and in general no tumor immune exclusion were observed.
    Journal • Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • POLE (DNA Polymerase Epsilon) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • B2M (Beta-2-microglobulin)
    |
    PD-L1 expression • PTEN mutation • POLE mutation • CD8-H
    10ms
    Tumoural Pellino-1 expression and Pellino-1-expressive cytotoxic T-cells are associated with poor prognosis in diffuse large B-cell lymphoma. (PubMed, Pathology)
    Pellino-1 expression was observed in both tumour cells and TILs, particularly in cytotoxic T-cells, and was correlated with poor outcomes in DLBCL. Thus, Pellino-1 might have an oncogenic effect on DLBCL and might be a potential target for improving cytotoxic T-cell activity.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • FOXP3 (Forkhead Box P3)
    |
    CD8-H
    10ms
    CD169 Expression in Lymph Nodes is Associated with Increased Infiltration of CD8 T Cells in Tumors: A Systematic Review and Meta-Analysis. (PubMed, J Immunol Res)
    However, the number and heterogeneity of the studies should be taken into consideration when evaluating the analysis. High-quality randomized controlled trials on the association between CD169 and CD8 expression are needed to verify these effects.
    Retrospective data • Review • Journal
    |
    CD8 (cluster of differentiation 8) • SIGLEC1 (Sialic Acid Binding Ig Like Lectin 1)
    |
    CD8 expression • CD69 overexpression • CD8-H
    10ms
    The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer. (PubMed, Breast Cancer Res Treat)
    High Ki-67 index, and high CD8 cell count are strong predictors for pCR in HER2-positive breast cancer. Tumours with high Ki-67 index, high TILs and CD8 infiltration may represent a subgroup where standard therapies are adequate. Conversely, those with low TILs and CD8 infiltration may identify a subgroup where use of novel strategies, including those that increase CD8 infiltration could be applied.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • HER-2 positive • CD8 positive • CD8-H • PD-L1 expression + CD8 positive
    10ms
    Macro CD5L deteriorates CD8T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma. (PubMed, Nat Commun)
    Anti-CTLA4 antibody reverses resistance of the therapy in intrahepatic cholangiocarcinoma. Our data provide a resource for predicting response of the combination therapy and highlight the importance of CD8T-cell status conversion and exhaustion induced by Macro CD5L in influencing the response, suggesting future avenues for cancer treatment optimization.
    Journal
    |
    CD8 (cluster of differentiation 8) • GZMB (Granzyme B) • GZMK (Granzyme K)
    |
    CD8-H
    |
    gemcitabine • Lenvima (lenvatinib) • oxaliplatin
    10ms
    The Association of Immune Cell Infiltration with Metastasis Location in De Novo Metastatic Triple Negative Breast Cancer: A Multicenter Cross-Sectional Study in Indonesia. (PubMed, Acta Med Indones)
    Furthermore, the majority (89.22%) of the patients showed No Special Type (NST), (56.7%) had histopathology grade III, high Ki-67 ≥20% (85.8%), and positive PD-L1 expression (30.8%), with visceral metastasis indicating the highest proportion of 75.8%. Patients with a high CD8/FOXP3 and CD4/FOXP3 ratio were significantly prone to have bone-only metastasis compared to visceral metastasis (p= 0.028 and p=0.024, respectively).  The ratio of antitumor to protumor T-lymphocytes had a significant relevance in the metastatic location patterns in TNBC.
    Observational data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases • Immune cell
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • CD8-H • FOXP3 expression
    11ms
    The prognostic value of CD8 CTLs, CD163 TAMs, and PDL1 expression in the tumor microenvironment of primary central nervous system lymphoma. (PubMed, Leuk Lymphoma)
    Survival analysis showed that high CD8 CTLs levels and high intratumoral PDL1 expression were significantly correlated with longer OS. High CD8 CTLs and CD163 TAMs levels were associated with longer PFS.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule)
    |
    PD-L1 expression • CD8-H
    11ms
    CXCL14 as a potential marker for immunotherapy response prediction in renal cell carcinoma. (PubMed, Ther Adv Med Oncol)
    Among the RCC cohort receiving nivolumab in Checkmate 025, the patients with CXCL14 high expression had better overall survival than those with CXCL14 low expression after immunotherapy...CXCL14 expression is associated with immunotherapy response in RCC. It is a promising biomarker for immunotherapy response prediction and may be an effective epigenetic modulator in combination with immunotherapy approaches.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL14 (C-X-C Motif Chemokine Ligand 14)
    |
    CD8 expression • CD8-H • CXCR4 expression
    |
    Opdivo (nivolumab)
    11ms
    The expression of SP263 in muscle invasive bladder carcinoma and its relationship with clinicopathological features. (PubMed, Indian J Pathol Microbiol)
    Our study results emphasize the importance of detecting PD-L1 expression in multiple tumor lesions from the same patient. In MIBC, CD8+ TIL density could be used as a prognostic marker for predicting the status of PD-L1 expression.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • CD8-H
    |
    VENTANA PD-L1 (SP263) Assay
    12ms
    Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial. (ASCO-GU 2024)
    Levels of tumor-infiltrating CD163-positive macrophages are associated with improved clinical outcomes to first-line nivolumab in pts with advanced ccRCC up to a density threshold, above which an association with poor outcomes is noted. Further investigations into the role of tumor-infiltrating myeloid cells in predicting outcomes to anti-PD-1-based therapies are ongoing. Clinical trial information: NCT05403541.
    Clinical • Clinical data • Metastases
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule)
    |
    CD8-H
    |
    Opdivo (nivolumab)
    12ms
    Prognostic significance of the frequencies of bone marrow lymphocyte subsets in adult acute myeloid leukemia at diagnosis. (PubMed, Int J Lab Hematol)
    The frequencies of BM lymphocyte subsets at diagnosis predicted clinical outcomes and could help improve risk stratification in AML.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    CD8-H